Germany is scouting trade fair halls and airport terminals to use as potential mass vaccination centres, as it draws up plans to inoculate the nation as soon as the first coronavirus shot gains European approval.
Berlin expects the first COVID-19 vaccines to be available in early 2021 and has given the country's 16 states a November 10 deadline to detail the addresses of 60 facilities to serve as delivery centres for manufacturers.
Under the strategy, approved by its cabinet last week, Germany has asked the states to identify central locations which will be supplemented by mobile teams who go into care homes.
The approach underscores the potential logistical challenges including limited supplies, multi-dose vials and complex storage requirements.
Some of the most advanced vaccines in human testing are so-called mRNA vaccines being developed by Moderna and the team of BioNTech and Pfizer Inc.
The BioNTech/Pfizer candidate needs to be stored at temperatures as low as minus 80 degrees.
That may give a slight edge to Moderna, whose vaccine is stored at minus 20, roughly the same as home freezer temperatures.
In smaller, city states such as Hamburg and Bremen, authorities are scouting for central locations that are easy to reach like exhibition halls, where vaccinations could be stockpiled.
"We are on the lookout for larger locations that are centrally located and spacious. This could well be the airport or trade fair," a spokesman for Hamburg's health ministry said.
Bigger, more rural states like Baden-Wuerttemberg and Schleswig-Holstein plan to distribute shots from a centralised delivery site into districts and towns.
Germany has asked the Robert Koch Institute's vaccine committee to identify which vulnerable population groups should get the shots first, although front-line workers are expected to be a priority.
In a second phase, when more vaccines are widely available in single-dose vials, Germany hopes to administer shots for the broader population at doctors' practices.
An electronic register will record who has been vaccinated, while an app is being developed to allow people to record potential side effects.
France has also been mulling plans for nationwide storage and distribution of vaccines but no firm details are yet available.